AtaiBeckley's Q4 loss widens on merger-related R&D costs

AtaiBeckley

06/03/2026 12:13

Overview

Biotechnology company's Q4 net loss widened substantially to $544.8 mln due to merger-related R&D costs

Company's cash position expected to fund operations into 2029

Outlook

Company anticipates BPL-003 Phase 3 trial initiation in Q2 2026

Company expects VLS-01 Phase 2 topline data in H2 2026

Cash runway expected to fund operations into early 2029

Result Drivers

MERGER-RELATED COSTS: Recorded non-cash acquisition of in-process R&D expenses of $527 mln related to combination with Beckley Psytech

FDA FEEDBACK - Successful End-of-Phase 2 meeting with FDA supports advancement of BPL-003 into Phase 3 studies for TRD

EMP-01 TRIAL RESULTS - Phase 2a trial of EMP-01 in SAD met primary safety objective and showed clinically meaningful improvements

Company press release: ID:nGNX7Br9xf

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
-$1.73
Q4 Net Income
-$544.84 mln
Q4 Operating Expenses
$571.05 mln
Q4 Operating Income
-$569.98 mln
Q4 Pretax Profit
-$544.92 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for AtaiBeckley Inc is $13.00, about 267.2% above its March 5 closing price of $3.54

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)